Individual differences |
Methods | Statistics | Clinical | Educational | Industrial | Professional items | World psychology |
Biological: Behavioural genetics · Evolutionary psychology · Neuroanatomy · Neurochemistry · Neuroendocrinology · Neuroscience · Psychoneuroimmunology · Physiological Psychology · Psychopharmacology (Index, Outline)
PBB Protein RYR1 image.jpg|
|OMIM||145600 154275 154276 600467 601887 601888|
Malignant hyperthermia (MH or MHS for "malignant hyperthermia syndrome", or "malignant hyperpyrexia due to anaesthesia") is a rare life-threatening condition that is triggered by exposure to certain drugs used for general anesthesia (specifically all volatile anesthetics), nearly all gas anesthetics, and the neuromuscular blocking agent succinylcholine. In susceptible individuals, these drugs can induce a drastic and uncontrolled increase in skeletal muscle oxidative metabolism which overwhelms the body's capacity to supply oxygen, remove carbon dioxide, and regulate body temperature, eventually leading to circulatory collapse and death if not treated quickly.
Susceptibility to MH is often inherited as an autosomal dominant disorder, for which there are at least 6 genetic loci of interest, most prominently the ryanodine receptor gene (RYR1). MH susceptibility is phenotypically and genetically related to central core disease (CCD), an autosomal dominant disorder characterized both by MH symptoms and myopathy. MH is usually unmasked by anesthesia, or when a family member develops the symptoms. There is no simple, straightforward test to diagnose the condition. When MH develops during a procedure, treatment with dantrolene sodium is usually initiated; dantrolene and the avoidance of anesthesia in susceptible people have markedly reduced the mortality from this condition.
Signs and symptoms[edit | edit source]
Malignant hyperthermia develops during or after receiving a general anaesthetic, and symptoms are generally identified by operating department staff. Characteristic signs are muscular rigidity, followed by a hypermetabolic state with increased oxygen consumption, increased carbon dioxide production (hypercapnia, usually measured by capnography), tachycardia (fast heart rate), and an increase in body temperature (hyperthermia) at a rate of up to ~2°C per hour; temperatures up to 42°C are not uncommon. Rhabdomyolysis (breakdown of muscle tissue) may develop, as evidenced by red-brown decoloration of the urine and cardiological or neurological evidence of electrolyte disturbances.[How to reference and link to summary or text]
Halothane, a once popular but now rarely used volatile anaesthetic, has been linked to a large proportion of cases, however, all halogenated volatile anaesthetics are potential triggers of malignant hyperthermia. Succinylcholine, a neuromuscular blocking agent, is also a trigger for MH. MH does not occur with every exposure to triggering agents, and susceptible patients may undergo multiple uneventful episodes of anesthesia before developing an episode of MH. The symptoms usually develop within one hour after exposure to trigger substances, but may even occur several hours later in rare instances.
A proportion of people susceptible to malignant hyperthermia may have particular characteristics. A 1972 report on a family with MH also described myopathy (muscle weakness due to muscle cell abnormality), short stature, cryptorchidism (undescended testicles), pectus carinatum (a chest wall deformity), lumbar lordosis and thoracic kyphosis (reversed curvature of the spine), and unusual facial characteristics. Later reports have termed this combinations the King-Denborough syndrome, after the authors of the report.
Diagnosis[edit | edit source]
During an attack[edit | edit source]
Malignant hyperthermia is diagnosed on clinical grounds, but various investigations are generally performed. This includes blood tests, which may show a raised creatine kinase level, elevated potassium, increased phosphate (leading to decreased calcium) and - if determined - raised myoglobin; this is the result of damage to muscle cells. Metabolic acidosis and respiratory acidosis (raised acidity of the blood) may both occur. Severe rhabdomyolysis may lead to acute renal failure, so kidney function is generally measured on a frequent basis.[How to reference and link to summary or text]
Susceptibility testing[edit | edit source]
In patients who have suffered an episode of MH, further tests are usually not performed as even a normal test would not mean that the patient is not at further risk of further episodes on future occasions. The exception would be if it is unclear whether the initial attack was due to a different medical problem, such as sepsis (severe infection).[How to reference and link to summary or text]
The main candidates for testing are those with a close relative who has suffered an episode of MH or has been shown to be susceptible. The standard procedure is the "caffeine-halothane contracture test", CHCT. A muscle biopsy is carried out at an approved research center, under local anesthesia. The fresh biopsy is bathed in solutions containing caffeine or halothane and observed for contraction; under good conditions, the sensitivity is 97% and the specificity 78%. Negative biopsies are not definitive, so any patient who is suspected of MH by their medical history or that of blood relatives is generally treated with non-triggering anesthetics even if the biopsy was negative. Some researchers advocate the use of the "calcium-induced calcium release" test in addition to the CHCT to make the test more specific.[How to reference and link to summary or text]
Less invasive diagnostic techniques have been proposed. Intramuscular injection of halothane 6 vol% has been shown to result in higher than normal increases in local pCO2 among patients with known malignant hyperthermia susceptibility. The sensitivity was 100% and specificity was 75%. For patients at similar risk to those in this study, this leads to a positive predictive value of 80% and negative predictive value of 100%. This method may provide a suitable alternative to more invasive techniques. A 2002 study examined another possible metabolic test. In this test, intramuscular injection of caffeine was followed by local measurement of the pCO2; those with known MH susceptibility had a significantly higher pCO2 (63 versus 44 mmHg). The authors propose larger studies to assess the test's suitability for determining MH risk.
A 2005 paper proposes a protocol for investigating people with a family history of MH, where first-line genetic screening of RYR1 mutations is one of the options.
Criteria[edit | edit source]
A 1994 consensus conference led to the formulation of a set of diagnostic criteria. The higher the score (above 6), the more likely a reaction constituted MH:
- Respiratory acidosis (end-tidal CO2 above 55 mmHg or arterial pCO2 above 60 mgHg)
- Heart involvement (unexplained sinus tachycardia, ventricular tachycardia or ventricular fibrillation)
- Metabolic acidosis (base excess lower than -8, pH<7.25)
- Muscle rigidity (generalized rigidity including severe masseter muscle rigidity)
- Muscle breakdown (CK >20,000/L units, cola colored urine or excess myoglobin in urine or serum, potassium above 6 mmol/l)
- Temperature increase (rapidly increasing temperature, T >38.8°C)
- Other (rapid reversal of MH signs with dantrolene, elevated resting serum CK levels)
- Family history (autosomal dominant pattern)
Pathophysiology[edit | edit source]
Disease mechanism[edit | edit source]
The potential for malignant hyperthermia is caused in a large proportion (50-70%) of cases by a mutation of the ryanodine receptor (type 1), located on the sarcoplasmic reticulum (SR), the organelle within skeletal muscle cells that stores calcium. RYR1 opens in response to increases in intracellular Ca2+ level mediated by L-type calcium channels, thereby resulting in a drastic increase in intracellular calcium levels and muscle contraction. RYR1 has two sites believed to be important for reacting to changing Ca2+ concentrations: the A-site and the I-site. The A-site is a high affinity Ca2+ binding site that mediates RYR1 opening. The I-site is a lower affinity site that mediates the protein's closing. Caffeine, Halothane, and other triggering agents act by drastically increasing the affinity of the A-site for Ca2+ and concomitantly decreasing the affinity of the I-site in mutant proteins. Mg2+ also affect RYR1 activity, causing the protein to close by acting at either the A- or I-sites. In MH mutant proteins, the affinity for Mg2+ at either one of these sites is greatly reduced. The end result of these alterations is greatly increased Ca2+ release due to a lowered activation and heightened deactivation threshold. The process of reabsorbing this excess Ca2+ consumes large amounts of ATP (adenosine triphosphate), the main cellular energy carrier, and generates the excessive heat (hyperthermia) that is the hallmark of the disease. The muscle cell is damaged by the depletion of ATP and possibly the high temperatures, and cellular constituents "leak" into the circulation, including potassium, myoglobin, creatine, phosphate and creatine kinase.
The other known causative gene for MH is CACNA1S, which encodes and L-type voltage-gated calcium channel α-subunit. There are two known mutations in this protein, both affecting the same residue, R1086. This residue is located in the large intracellular loop connecting domains 3 and 4, a domain possibly involved in negatively regulating RYR1 activity. When these mutant channels are expressed in HEK 293 (human embryonic kidney) cells, the resulting channels are five times more sensitive to activation by caffeine (and presumably halothane) and activate at 5-10mV more hyperpolarized. Furthermore, cells expressing these channels have an increased basal cytosolic Ca2+ concentration. As these channels interact with and activate RYR1, these alterations result in a drastic increase of intracellular Ca2+, and, thereby, muscle excitability.
Other mutations causing MH have been identified, although in most cases the relevant gene remains to be identified.
Animal model[edit | edit source]
Research into malignant hyperthermia was limited until the discovery of "porcine stress syndrome" in Landrace pigs, a condition in which stressed pigs develop "pale, soft, exudative" flesh (a manifestation of the effects of malignant hyperthermia) rendering their meat unmarketable at slaughter. This "awake triggering" was not observed in humans, and initially cast doubts on the value of the animal model, but subsequently susceptible humans were discovered to "awake trigger" (develop malignant hyperthermia) in stressful situations. This supported the use of the pig model for research. Pig farmers use halothane cones in swine yards to expose piglets to halothane. Those that die were MH-susceptible, thus saving the farmer the expense of raising a pig whose meat he would not be able to market.[How to reference and link to summary or text]
Gillard et al discovered the causative mutation in humans only after similar mutations had first been described in pigs.
Horses also suffer from malignant hyperthermia. It is the Thoroughbred breed that was found to have susceptibility. It can be caused by overwork, anesthesia, or stress. An inheritable genetic mutation is found in susceptible animals. 
An MH mouse has been constructed, bearing the R163C mutation prevalent in humans. These mice display symptoms similar to human MH patients, including sensitivity to halothane (increased respiration, body temperature, and death). Blockade of RYR1 by dantrolene prevents adverse reaction to halothane in these mice, as with humans. Muscle from these mice also shows increased K+-induced depolarization and an increased caffeine sensitivity.
Genetics[edit | edit source]
At least 70 mutations in the ryanodine receptor have been described, which are transmitted in an autosomal dominant fashion. The gene is located on the long arm of the nineteenth chromosome (19q13.1). These mutations tend to cluster in one of three domains within the protein, designated MH1-3. MH1 and MH2 are located in the N-terminus of the protein, which interacts with L-type calcium channels and Ca2+. MH3 is located in the transmembrane forming C-terminus. This region is important for allowing Ca2+ passage through the protein following opening.[How to reference and link to summary or text]
Treatment[edit | edit source]
The current treatment of choice is the intravenous administration of dantrolene, the only known antidote, discontinuation of triggering agents, and supportive therapy directed at correcting hyperthermia, acidosis, and organ dysfunction. Treatment must be instituted rapidly on clinical suspicion of the onset of malignant hyperthermia.[How to reference and link to summary or text]
Dantrolene is a muscle relaxant that appears to work directly on the ryanodine receptor to prevent the release of calcium. After the widespread introduction of treatment with dantrolene the mortality of malignant hyperthermia fell from 80% in the 1960s to less than 10%. Dantrolene remains as the only drug known to be effective in the treatment of MH.
Its clinical use has been limited by its low water solubility, leading to requirements of large fluid volumes which may complicate clinical management. Azumolene is a 30-fold more water-soluble analogue of dantrolene that also works to decrease the release of intracellular calcium by its action on the ryanodine receptor. In MH susceptible swine, azumolene was as potent as dantrolene. It has yet to be studied in vivo in humans, but may present a suitable alternative to dantrolene in the treatment of MH.
Prevention[edit | edit source]
In the past, the prophylactic use of dantrolene was recommended for MH susceptible patients undergoing general anesthesia. However, multiple retrospective studies, have demonstrated the safety of trigger-free general anesthesia in these patients in the absence of prophylactic dantrolene administration. The largest of these studies looked at the charts of 2214 patients who underwent general or regional anesthesia for an elective muscle biopsy. 1082 of the patients were muscle biopsy positive for MH. Only five of these patients exhibited symptoms consistent with MH, four of which were treated successfully with parenteral dantrolene, and the remaining one recovered with only symptomatic therapy. After weighing its questionable benefits against its possible adverse effects, experts no longer recommend the use of prophylactic dantrolene prior to trigger-free general anesthesia in MH susceptible patients.
The only sure way to prevent MH is avoid the use of triggering agents in patients known or suspected of being susceptible to MH.[How to reference and link to summary or text]
Epidemiology[edit | edit source]
The incidence has been reported to be between 1:4,500 to 1:60,000 procedures involving general anaesthesia. This disorder occurs worldwide and affects all racial groups. Most cases however occur in children and young adults, which might be related to the fact that many older people will have already had surgeries and thus would know about and be able to avoid this condition.[How to reference and link to summary or text]
History[edit | edit source]
The syndrome was first recognized in Australia in an affected family by Denborough et al in 1962. Similar reactions were found in pigs. After animal studies indicated possible benefit from dantrolene, a 1982 study confirmed its usefulness in humans.
References[edit | edit source]
- Litman R, Rosenberg H (2005). Malignant hyperthermia: update on susceptibility testing. JAMA 293 (23): 2918–24.
- King JO, Denborough MA, Zapf PW (1972). Inheritance of malignant hyperpyrexia. Lancet 1 (7746): 365–70.
- Allen G, Larach M, Kunselman A (1998). The sensitivity and specificity of the caffeine-halothane contracture test: a report from the North American Malignant Hyperthermia Registry. Anesthesiology 88 (3): 579–88.
- Schuster F, Gardill A, Metterlein T, Kranke P, Roewer N, Anetseder M (2007). A minimally invasive metabolic test with intramuscular injection of halothane 5 and 6 vol% to detect probands at risk for malignant hyperthermia. Anaesthesia 62 (9): 882–7.
- Anetseder M, Hager M, Müller CR, Roewer N (2002). Diagnosis of susceptibility to malignant hyperthermia by use of a metabolic test. Lancet 359 (9317): 1579–80.
- Larach MG, Localio AR, Allen GC, et al (1994). A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology 80 (4): 771–9.
- Gillard E, Otsu K, Fujii J, Khanna V, de Leon S, Derdemezi J, Britt B, Duff C, Worton R, MacLennan D (1991). A substitution of cysteine for arginine 614 in the ryanodine receptor is potentially causative of human malignant hyperthermia. Genomics 11 (3): 751–5.
- Galli L, Orrico A, Lorenzini S, Censini S, Falciani M, Covacci A, Tegazzin V, Sorrentino V (2006). Frequency and localization of mutations in the 106 exons of the RYR1 gene in 50 individuals with malignant hyperthermia. Hum Mutat 27 (8): 830.
- Balog E, Fruen B, Shomer N, Louis C (2001). Divergent effects of the malignant hyperthermia-susceptible Arg(615)->Cys mutation on the Ca(2+) and Mg(2+) dependence of the RyR1. Biophys J 81 (4): 2050–8. Full text at PMC: 1301678
- Yang T, Ta T, Pessah I, Allen P (2003). Functional defects in six ryanodine receptor isoform-1 (RyR1) mutations associated with malignant hyperthermia and their impact on skeletal excitation-contraction coupling. J Biol Chem 278 (28): 25722–30.
- Monnier N, Procaccio V, Stieglitz P, Lunardi J (1997). Malignant-hyperthermia susceptibility is associated with a mutation of the alpha 1-subunit of the human dihydropyridine-sensitive L-type voltage-dependent calcium-channel receptor in skeletal muscle. Am J Hum Genet 60 (6): 1316–25. Full text at PMC: 1716149
- The R1086C mutant has never been published, but has nevertheless been referenced multiple times in the literature, e.g. Jurkat-Rott K, McCarthy T, Lehmann-Horn F (2000). Genetics and pathogenesis of malignant hyperthermia. Muscle Nerve 23 (1): 4–17.
- Weiss R, O'Connell K, Flucher B, Allen P, Grabner M, Dirksen R (2004). Functional analysis of the R1086H malignant hyperthermia mutation in the DHPR reveals an unexpected influence of the III-IV loop on skeletal muscle EC coupling. Am J Physiol Cell Physiol 287 (4): C1094–102.
- Valberg SJ, Mickelson JR, Gallant EM, MacLeay JM, Lentz L, de la Corte F (1999). Exertional rhabdomyolysis in quarter horses and thoroughbreds: one syndrome, multiple aetiologies. Equine Vet J Suppl 30: 533–8.
- Yang T, Riehl J, Esteve E, et al (2006). Pharmacologic and functional characterization of malignant hyperthermia in the R163C RyR1 knock-in mouse. Anesthesiology 105 (6): 1164–75.
- Krause T, Gerbershagen MU, Fiege M, Weisshorn R, Wappler F (2004). Dantrolene--a review of its pharmacology, therapeutic use and new developments. Anaesthesia 59 (4): 364–73.
- Dershwitz M, Sréter FA (1990). Azumolene reverses episodes of malignant hyperthermia in susceptible swine. Anesth. Analg. 70 (3): 253–5.
- Carr AS, Lerman J, Cunliffe M, McLeod ME, Britt BA (1995). Incidence of malignant hyperthermia reactions in 2,214 patients undergoing muscle biopsy. Can J Anaesth 42 (4): 281–6.
- Denborough MA, Forster JF, Lovell RR, Maplestone PA, Villiers JD (1962). Anaesthetic deaths in a family. British journal of anaesthesia 34: 395–6. Historical account in Denborough MA (2008). Malignant hyperthermia. 1962. Anesthesiology 108 (1): 156–7.
- Hall LW, Woolf N, Bradley JW, Jolly DW (1966). Unusual reaction to suxamethonium chloride. Br Med J 2 (5525): 1305. Full text at PMC: 1944316
- Kolb ME, Horne ML, Martz R (1982). Dantrolene in human malignant hyperthermia. Anesthesiology 56 (4): 254–62.
[edit | edit source]
- Malignant Hyperthermia Association of the United States
- Making Anesthesia Safer - Unraveling the Malignant Hyperthermia Puzzle by Marilyn Green Larach, FASEB "Breakthroughs in Bioscience"